DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
This grant funds research to develop or validate clinical outcomes and biomarkers for ALS, including digital health measures, with input from the ALS community to improve clinical trials.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 24, 2026: Pre-Application (Preproposal) | September 30, 2026: Full Application | October 6, 2026: Application Verification Period End
Funding Amounts: Total program funding: $7,000,000; up to $1,000,000 total costs per award over 3 years; ~7 awards expected.
Summary: Supports development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS).
Key Information: Clinical trials are not allowed; community collaboration is required in all proposals.
Description
This opportunity funds research focused on the development and/or validation of clinical outcomes and biomarkers to enhance clinical trials in amyotrophic lateral sclerosis (ALS). Projects may target specific therapies, classes of therapeutics, or ALS subtypes, and are not required to be broadly applicable to all ALS patients. The award is intended to support studies that identify, develop, or validate ALS-specific biomarkers (e.g., susceptibility/risk, diagnostic, prognostic, predictive, response, safety) and/or clinical outcome measures (e.g., clinician-, observer-, patient-reported, or performance outcomes). Use of digital health measures (wearables, smartphone sensors, imaging, etc.) is encouraged. All projects must include meaningful collaboration with the ALS lived experience community.
Clinical trials are not permitted under this mechanism, but prospective patient enrollment for biospecimen or data collection is allowed. The program prioritizes research that leverages existing clinical resources, biorepositories, or datasets, and that demonstrates clear plans for data and resource sharing.
